

## Appendix H. Ongoing Studies

Trial Identifier	Study Name	Location	Participants N	Intervention	Outcome Measures	Status Aug 2018
NCT01756833	Non-Invasive Treatment of Abdominal Aortic Aneurysm Clinical Trial (N-TA <sup>3</sup> CT) Michael Terrin	US	Men and women age 55 years and older N=261	Doxycycline 100 mg po bid for 2 years vs. placebo	AAA growth	Active, expected completion 2019.  <a href="#">Protocol</a> published 2016
NCT01683084	Study of the Effectiveness of Telmisartan in Slowing the Progression of Abdominal Aortic Aneurysms (TEDY) (Ronald L Dalman)	US	Adults ages 50 to 85 years N=22	Telmisartan 40 mg daily for 24 mo vs. placebo	Rate of AAA growth, AAA diameter, AAA biomarkers, QoL	Completed 2016. No result publication found.  <a href="#">Protocol</a> published 2015
NCT02717481	Using US to Evaluate Aortic Aneurysm Size Based on 3D Co-registration to Previous CT Scan (Diana Gaitini)	Israel	Men and women age 18 years and older diagnosed with AAA or following invasive repair N=120	Ultrasound	Primary: Exact and reliable evaluation of the aneurysm size Secondary: The size difference between systolic and diastolic aneurysm; aneurysm neck size and changes following an invasive procedure to repair it (EVAR); evaluation of the pressure on the aneurysmal wall	Not yet recruiting, expected completion 2018
NCT01205945	The Effect of Abdominal Aortic Aneurysm Screening on Mortality in Asian Population (Jin Hyun Joh)	South Korea	Men and women ages 50 to 85 years with CVD risk factors, family history of AAA N=12,000	Ultrasound	Benefits of screening older population	Ongoing, estimated completion 2017. No publications found.
NCT02345590	Eplerenone in the Management of Abdominal Aortic Aneurysms (Leah Isles)	Australia	Men and women ages 60 to 90 years with AAA 30 to 49 mm N=172	Eplerenone 25mg/day vs. placebo	AAA maximum orthogonal diameter	Ongoing, estimated completion 2019.
NCT02229006	Sodium Fluoride Imaging of Abdominal Aortic Aneurysms (SoFIA3) (Rachael O Forsythe)	UK	Men and women age 50 years and older in MA3RS study with AAA >40 mm N=100	Radiation: 18F-NaF PET-CT	Primary: Change in AAA anteroposterior diameter at 6 and 12 months measured with CTA Secondary: Co-localization of 18F-NaF with USPIO uptake on MRI scanning	Completed 2017. No publications found.

## Appendix H. Ongoing Studies

Trial Identifier	Study Name	Location	Participants N	Intervention	Outcome Measures	Status Aug 2018
NCT02604303	A Prospective Analysis on the Expansion Rates of Abdominal Aortic Aneurysms (Eugene S. Lee)	US	Veteran men and women age 21 years and older screened for AAA by VA N=200	Observational using screening	Primary: aortic expansion rate measured with ultrasound Secondary: RhoA levels	Ongoing, expected completion Nov 2018.
NCT02070653	The Efficacy of Ticagrelor on Abdominal Aortic Aneurysm (AAA) Expansion (TicAAA) (Anders Wanhainen)	Sweden	Men and women ages 50 to 85 years with AAA 35 to 49 mm N=145	Ticagrelor 180 mg/day vs. placebo	Primary: AAA volume growth measured with MRI Secondary: AAA diameter growth measured with ultrasound and MRI; need for surgery; rupture	Completed 2018. No publications found.
NCT02548546	Estimation of Biomechanical Aortic Wall Properties in Healthy and Aneurysmal Aortas Using Novel Imaging Techniques (Houssam Farres)	US	Men and women age 21 years and older with AAA $\geq 1.5x$ normal diameter N=30	Surveillance vs. open repair vs. EVAR	Primary: ECHO imaging Secondary: ECG-gated MRA imaging	Ongoing (recruiting), expected completion Aug 2018.
NCT02225756	Cyclosporine A in Patients With Small Diameter Abdominal Aortic Aneurysms (ACA4) (Eric Allaire)	France	Men with AAA 30 to 49 mm, women with AAA 25 to 44 mm, 50 to 85 years N=360	Cyclosporine vs. placebo	Primary: AAA diameter evolution on CT-scanner 12 months after treatment interruption Secondary: AAA diameter evolution on duplex-scanner 12 months after treatment interruption; all-cause CV mortality/morbidity	Ongoing (recruiting), expected completion Sep 2018.
NCT02022436	Evaluation of Predictors of Aortic Aneurysm Growth and Rupture (Rabih Chaer)	US	Men and women age 21 years and older diagnosed with AAA N=148	Contrast ultrasound	Primary: time to growth and/or rupture of abdominal aortic aneurysm Secondary: AAA biomarkers	Ongoing (recruiting), expected completion Jul 2020.
NCT02179801	Screening Cardiovascular Patients for Aortic aNeurysms (SCAN) (Hans-Henning Eckstein, Karl-Ludwig Laugwitz)	Germany	Men any age with 1 or more risk factors for AAA and coronary artery intervention N=1,000	Ultrasound screening	Primary: prevalence of AAA Secondary: prevalence of AAA in the cohort requiring treatment; correlation of risk factors for AAA with risk factors for CAD; distribution of risk factors	Ongoing (recruiting), expected completion Apr 2018. No publications found.

## Appendix H. Ongoing Studies

Trial Identifier	Study Name	Location	Participants N	Intervention	Outcome Measures	Status Aug 2018
NCT02846883	Safety and Efficacy of Allogeneic MSCs in Promoting T-regulatory Cells in Patients With Small Abdominal Aortic Aneurysms (VIVAAA) (Michael Patrick Murphy, Richard L. Roudebush)	US	Men and women ages 40 to 80 years diagnosed with AAA 35 to 45 mm	Intravenous infusion of 1 or 3 million allogeneic MSCs/kg vs. placebo	Primary: incidence of treatment-related adverse events at 12 months Secondary: changes in inflammatory AAA biomarkers; change in aortic inflammation measured by 18-FDG PET/CT	Ongoing (recruiting), expected completion 2021.
ISRCTN10945166	Abdominal Aortic Aneurysm Screening by Ultrasonography in Primary Care (Ana Claveria)	Spain	Men ages 65 to 74 years N=3,348	Screening	Primary: impact of early diagnosis on overall/CV mortality with incidental AAA Secondary: CV mortality; surgery for AAA; type of hospital discharge	Ongoing, expected completion 2021.
NCT01420991	Brain and Abdominal Aneurysm Study (BAAS) (James Meschia)	US	Men and women age 18 years and older diagnosed with intracranial aneurysm N=81	Opportunistic screening	Primary: prevalence of AAA Secondary: functional outcomes at 30 days	Ongoing, expected completion 2024.
NCT00662480	Randomized Preventive Vascular Screening Trial of 65-74 Year Old Men in the Central Region of Denmark (VIVA)	Denmark	40,000	Screening for hypertension, lower limb atherosclerosis, and abdominal aortic aneurysm	All-cause mortality, cardiovascular events	Active, expected completion Dec 2023.  Median (4.4 year) results published in 2017. <sup>146</sup>
ISRCTN12157806	The Danish Cardiovascular Screening Trial (DANCAVAS) (Jes Lindholt)	Denmark	45,000	Large population-based, randomized, clinical multicenter trial testing combination cardiovascular screening in men ages 65 to 74 years	All-cause mortality, costs, and cost-effectiveness after 3, 5, and 10 years to assess possible health and/or societal benefits of the screening; nationwide registry-based information on health care consumption	Ongoing, expected completion Jan 2026.  <a href="#">Protocol</a> published 2015.